Fort Washington Investment Advisors Inc. OH Makes New $15.62 Million Investment in Omnicell, Inc. $OMCL

Key Points

• Fort Washington Investment Advisors acquired 458,751 Omnicell shares worth approximately $15.62 million, giving it a 1.01% stake. Institutional investors and hedge funds collectively own 97.70% of OMCL.
• Analysts maintain a generally positive outlook, with seven Buy ratings and two Holds, producing a consensus “Moderate Buy” rating and an average price target of $57.86.
• Omnicell’s latest quarterly results exceeded expectations, with EPS of $0.94 versus the $0.47 consensus estimate and revenue of $312.21 million, up 7.4% year over year.

Fort Washington Investment Advisors Inc. OH bought a new stake in Omnicell, Inc. (NASDAQ:OMCL - Free Report) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 458,751 shares of the company's stock, valued at approximately $15,620,000. Fort Washington Investment Advisors Inc. OH owned 1.01% of Omnicell at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. BlackRock Inc. purchased a new stake in Omnicell during the 2nd quarter worth $313,044,000. First Light Asset Management LLC acquired a new position in Omnicell in the 1st quarter worth $16,351,000. WCM Investment Management LLC acquired a new position in Omnicell in the 1st quarter worth $9,783,000. Empowered Funds LLC boosted its position in Omnicell by 4,229.9% in the 1st quarter. Empowered Funds LLC now owns 262,043 shares of the company's stock valued at $8,747,000 after buying an additional 255,991 shares during the last quarter. Finally, Burney Co. purchased a new position in Omnicell in the 1st quarter valued at about $7,118,000. 97.70% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on OMCL. Wells Fargo & Company lowered their target price on Omnicell from $55.00 to $50.00 and set an "overweight" rating for the company in a research note on Friday, July 31st. KeyCorp reaffirmed an "overweight" rating on shares of Omnicell in a research report on Monday, August 24th. Piper Sandler reiterated an "overweight" rating and issued a $45.00 price target (down from $55.00) on shares of Omnicell in a research note on Monday, August 3rd. Weiss Ratings upgraded Omnicell from a "hold (c-)" rating to a "hold (c)" rating in a research note on Tuesday, August 18th. Finally, Zacks Research raised Omnicell from a "strong sell" rating to a "hold" rating in a report on Monday, September 7th. Seven investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat, Omnicell currently has a consensus rating of "Moderate Buy" and a consensus price target of $57.86.

Omnicell Stock Up 1.6%

OMCL stock opened at $35.95 on Friday. The company has a current ratio of 1.64, a quick ratio of 1.43 and a debt-to-equity ratio of 0.13. The firm has a 50 day simple moving average of $34.59 and a 200-day simple moving average of $38.50. The company has a market capitalization of $1.63 billion, a P/E ratio of 42.80, a PEG ratio of 0.89 and a beta of 0.98. Omnicell, Inc. has a twelve month low of $29.09 and a twelve month high of $55.00.

Omnicell (NASDAQ:OMCL - Get Free Report) last posted its quarterly earnings results on Thursday, July 30th. The company reported $0.94 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.47 by $0.47. Omnicell had a net margin of 3.13% and a return on equity of 5.66%. The firm had revenue of $312.21 million for the quarter, compared to analysts' expectations of $310.21 million. During the same period in the prior year, the company posted $0.45 earnings per share. The firm's quarterly revenue was up 7.4% on a year-over-year basis. Omnicell has set its Q3 2026 guidance at 0.350-0.430 EPS and its FY 2026 guidance at 2.150-2.300 EPS. On average, equities research analysts predict that Omnicell, Inc. will post 1.41 earnings per share for the current fiscal year.

Omnicell Company Profile

Omnicell, Inc provides medication-management technology and related services for health care providers. Its solutions are designed to help hospitals, health systems, retail pharmacies and other care settings manage medication inventory, improve workflow efficiency and support medication adherence.

The company's offerings include automated medication dispensing systems, central pharmacy automation, medication packaging and adherence solutions, pharmacy inventory management tools, and software for medication-use analytics and workflow management.

Want to see what other hedge funds are holding OMCL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omnicell, Inc. (NASDAQ:OMCL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.